Skip to main content
Top
Published in: Antimicrobial Resistance & Infection Control 1/2020

01-12-2020 | Levofloxacin | Research

Development of in vitro resistance to fluoroquinolones in Pseudomonas aeruginosa

Authors: Lei Zhao, Shiqi Wang, Xiaobing Li, Xiaojing He, Lingyan Jian

Published in: Antimicrobial Resistance & Infection Control | Issue 1/2020

Login to get access

Abstract

Fluoroquinolone resistance in Pseudomonas aeruginosa typically arises through site-specific mutations and overexpression of efflux pumps. In this study, we investigated the dynamics of different resistance mechanisms in P. aeruginosa populations that have evolved under fluoroquinolone pressure, as well as the interactions between these mechanisms in evolutionary trajectories. Bacteria of strain ATCC27853 were selected under different concentrations of ciprofloxacin and levofloxacin for six parallel lineages, followed by amplification of four target genes in the quinolone-resistance determining region (QRDR) and Sanger sequencing to identify the mutations. The expression of four efflux pump proteins was evaluated by real-time polymerase chain reaction using the relative quantitation method, with the ATCC27853 strain used as a control. We found that ciprofloxacin killed P. aeruginosa sooner than did levofloxacin. Further, we identified five different mutations in three subunits of QRDRs, with gyrA as the main mutated gene associated with conferring fluoroquinolone resistance. Additionally, we found a larger number of mutations appearing at 2 mg/L and 4 mg/L of ciprofloxacin and levofloxacin, respectively. Moreover, we identified the main efflux pump being expressed as MexCD-OprJ, with initial overexpression observed at 0.25 mg/L and 0.5 mg/L of ciprofloxacin and levofloxacin, respectively. These results demonstrated gyrA83 mutation and MexCD-OprJ overexpression as the primary mechanism conferring ciprofloxacin and levofloxacin resistance in P. aeruginosa. In addition, we also show that ciprofloxacin exhibited a stronger ability to kill the bacteria while potentially rendering it more susceptible to resistance.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bhagirath AY, Li Y, Somayajula D, Dadashi M, Badr S, Duan K. Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm Med. 2016;16:174.CrossRef Bhagirath AY, Li Y, Somayajula D, Dadashi M, Badr S, Duan K. Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm Med. 2016;16:174.CrossRef
2.
go back to reference Engler K, Muhlemann K, Garzoni C, Pfahler H, Geiser T, von Garnier C. Colonisation with Pseudomonas aeruginosa and antibiotic resistance patterns in COPD patients. Swiss Med Wkly. 2012;142:w13509.PubMed Engler K, Muhlemann K, Garzoni C, Pfahler H, Geiser T, von Garnier C. Colonisation with Pseudomonas aeruginosa and antibiotic resistance patterns in COPD patients. Swiss Med Wkly. 2012;142:w13509.PubMed
3.
go back to reference Bruchmann S, Dotsch A, Nouri B, Chaberny IF, Haussler S. Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance. Antimicrob Agents Chemother. 2013;57:1361–8.CrossRef Bruchmann S, Dotsch A, Nouri B, Chaberny IF, Haussler S. Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance. Antimicrob Agents Chemother. 2013;57:1361–8.CrossRef
4.
go back to reference Zhang G, Wang C, Sui Z, Feng J. Insights into the evolutionary trajectories of fluoroquinolone resistance in Streptococcus pneumoniae. J Antimicrob Chemother. 2015;70:2499–506.CrossRef Zhang G, Wang C, Sui Z, Feng J. Insights into the evolutionary trajectories of fluoroquinolone resistance in Streptococcus pneumoniae. J Antimicrob Chemother. 2015;70:2499–506.CrossRef
5.
go back to reference Llanes C, Kohler T, Patry I, Dehecq B, van Delden C, Plesiat P. Role of the MexEF-OprN efflux system in low-level resistance of Pseudomonas aeruginosa to ciprofloxacin. Antimicrob Agents Chemother. 2011;55:5676–84.CrossRef Llanes C, Kohler T, Patry I, Dehecq B, van Delden C, Plesiat P. Role of the MexEF-OprN efflux system in low-level resistance of Pseudomonas aeruginosa to ciprofloxacin. Antimicrob Agents Chemother. 2011;55:5676–84.CrossRef
6.
go back to reference Jansen G, Barbosa C, Schulenburg H. Experimental evolution as an efficient tool to dissect adaptive paths to antibiotic resistance. Drug Resist Updat. 2013;16:96–107.CrossRef Jansen G, Barbosa C, Schulenburg H. Experimental evolution as an efficient tool to dissect adaptive paths to antibiotic resistance. Drug Resist Updat. 2013;16:96–107.CrossRef
7.
go back to reference Zhang Q, Lambert G, Liao D, Kim H, Robin K, Tung CK, Pourmand N, Austin RH. Acceleration of emergence of bacterial antibiotic resistance in connected microenvironments. Science. 2011;333:1764–7.CrossRef Zhang Q, Lambert G, Liao D, Kim H, Robin K, Tung CK, Pourmand N, Austin RH. Acceleration of emergence of bacterial antibiotic resistance in connected microenvironments. Science. 2011;333:1764–7.CrossRef
9.
go back to reference Turkmani A, Psaroulaki A, Christidou A, Chochlakis D, Tabaa D, Tselentis Y. In vitro-selected resistance to fluoroquinolones in two Brucella strains associated with mutational changes in gyrA. Int J Antimicrob Agents. 2008;32:227–32.CrossRef Turkmani A, Psaroulaki A, Christidou A, Chochlakis D, Tabaa D, Tselentis Y. In vitro-selected resistance to fluoroquinolones in two Brucella strains associated with mutational changes in gyrA. Int J Antimicrob Agents. 2008;32:227–32.CrossRef
10.
go back to reference Achtman M, Wagner M. Microbial diversity and the genetic nature of microbial species. Nat Rev Microbiol. 2008;6:431–40.CrossRef Achtman M, Wagner M. Microbial diversity and the genetic nature of microbial species. Nat Rev Microbiol. 2008;6:431–40.CrossRef
11.
go back to reference Yang X, Xing B, Liang C, Ye Z, Zhang Y. Prevalence and fluoroquinolone resistance of pseudomonas aeruginosa in a hospital of South China. Int J Clin Exp Med. 2015;8:1386–90.PubMedPubMedCentral Yang X, Xing B, Liang C, Ye Z, Zhang Y. Prevalence and fluoroquinolone resistance of pseudomonas aeruginosa in a hospital of South China. Int J Clin Exp Med. 2015;8:1386–90.PubMedPubMedCentral
12.
go back to reference Pasca MR, Dalla Valle C, De Jesus Lopes Ribeiro AL, Buroni S, Papaleo MC, Bazzini S, Udine C, Incandela ML, Daffara S, Fani R, et al. Evaluation of fluoroquinolone resistance mechanisms in Pseudomonas aeruginosa multidrug resistance clinical isolates. Microb Drug Resist. 2012;18:23–32.CrossRef Pasca MR, Dalla Valle C, De Jesus Lopes Ribeiro AL, Buroni S, Papaleo MC, Bazzini S, Udine C, Incandela ML, Daffara S, Fani R, et al. Evaluation of fluoroquinolone resistance mechanisms in Pseudomonas aeruginosa multidrug resistance clinical isolates. Microb Drug Resist. 2012;18:23–32.CrossRef
13.
go back to reference Khalil D, Becker CAM, Tardy F. Alterations in the quinolone resistance-determining regions and Fluoroquinolone resistance in clinical isolates and laboratory-derived mutants of mycoplasma bovis: not all genotypes may be equal. Appl Environ Microbiol. 2016;82:1060–8.CrossRef Khalil D, Becker CAM, Tardy F. Alterations in the quinolone resistance-determining regions and Fluoroquinolone resistance in clinical isolates and laboratory-derived mutants of mycoplasma bovis: not all genotypes may be equal. Appl Environ Microbiol. 2016;82:1060–8.CrossRef
14.
go back to reference Lee JK, Lee YS, Park YK, Kim BS. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2005;25:290–5.CrossRef Lee JK, Lee YS, Park YK, Kim BS. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2005;25:290–5.CrossRef
15.
go back to reference Terzi HA, Kulah C, Ciftci IH. The effects of active efflux pumps on antibiotic resistance in Pseudomonas aeruginosa. World J Microbiol Biotechnol. 2014;30:2681–7.CrossRef Terzi HA, Kulah C, Ciftci IH. The effects of active efflux pumps on antibiotic resistance in Pseudomonas aeruginosa. World J Microbiol Biotechnol. 2014;30:2681–7.CrossRef
16.
go back to reference Shigemura K, Osawa K, Kato A, Tokimatsu I, Arakawa S, Shirakawa T, Fujisawa M. Association of overexpression of efflux pump genes with antibiotic resistance in Pseudomonas aeruginosa strains clinically isolated from urinary tract infection patients. J Antibiotics. 2015;68:568–72.CrossRef Shigemura K, Osawa K, Kato A, Tokimatsu I, Arakawa S, Shirakawa T, Fujisawa M. Association of overexpression of efflux pump genes with antibiotic resistance in Pseudomonas aeruginosa strains clinically isolated from urinary tract infection patients. J Antibiotics. 2015;68:568–72.CrossRef
Metadata
Title
Development of in vitro resistance to fluoroquinolones in Pseudomonas aeruginosa
Authors
Lei Zhao
Shiqi Wang
Xiaobing Li
Xiaojing He
Lingyan Jian
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Antimicrobial Resistance & Infection Control / Issue 1/2020
Electronic ISSN: 2047-2994
DOI
https://doi.org/10.1186/s13756-020-00793-8

Other articles of this Issue 1/2020

Antimicrobial Resistance & Infection Control 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.